ArticleEuropean radiology experimental2026
Automated three-dimensional radiomic body composition analysis enhances survival prediction in resectable non‑small cell lung cancer.
Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveTo develop and validate a machine learning radiomics model integrating automated three-dimensional body composition and tumor imaging features for predicting overall survival in resectable non-small cell lung cancer (NSCLC). MATERIALS AND
methodsThis multicenter retrospective study included patients with resectable NSCLC treated between January 2013 and December 2017, who were assigned to training, internal, and external validation cohorts. A fully automated deep learning algorithm was developed for body composition segmentation. Radiomic features from tumor and body composition were extracted and integrated using extreme gradient boosting. Model performance was assessed using the concordance index (C-index) and time-dependent area under the curve (AUC), with interpretability evaluated by SHapley Additive exPlanations (SHAP). Kaplan-Meier analysis was performed for survival stratification.
resultsAmong 1,038 patients (mean age, 61.8 ± 10.7 years; 58.66% male), 293 (28.2%) died over a median follow-up of 3.31 years. In the training cohort, both tumor score and body composition score were independently associated with overall survival (hazard ratio 2.72 and 2.03, respectively; all p < 0.001). Incorporating body composition radiomics significantly improved discrimination compared with tumor-only models across cohorts (all p < 0.05). The comprehensive model, integrating clinicopathological factors, tumor score, and body composition score, demonstrated strong predictive capability for 1, 2, 3, and 5-year survival (AUCs > 0.80). SHAP analysis identified tumor score and body composition score as dominant predictors, stratifying patients into four phenotypes with distinct prognoses (all log-rank p < 0.05).
conclusionIntegrating automated three-dimensional body composition with tumor radiomics enhances survival prediction and provides incremental value for postoperative risk stratification in resectable NSCLC. KEY POINTS: Question Standard staging for resectable non-small cell lung cancer lacks objective three-dimensional quantification of host body composition, thereby limiting individualized prognostic assessment. Findings Machine learning models integrating automated three-dimensional body composition and tumor radiomics significantly outperform conventional tumor imaging in overall survival prediction. Relevance statement Automated three-dimensional body composition radiomics integrated with tumor imaging improves survival prediction in resectable non-small cell lung cancer, enabling more precise postoperative risk stratification and supporting individualized follow-up and supportive care strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.